BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 15509511)

  • 21. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
    Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
    Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
    Post DE; Devi NS; Li Z; Brat DJ; Kaur B; Nicholson A; Olson JJ; Zhang Z; Van Meir EG
    Clin Cancer Res; 2004 Dec; 10(24):8603-12. PubMed ID: 15623644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
    Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
    Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
    Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
    Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HIF1alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element.
    Farrall AL; Whitelaw ML
    Oncogene; 2009 Oct; 28(41):3671-80. PubMed ID: 19668230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
    Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses.
    Schmitz M; Graf C; Gut T; Sirena D; Peter I; Dummer R; Greber UF; Hemmi S
    Gene Ther; 2006 Jun; 13(11):893-905. PubMed ID: 16482201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
    Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
    Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter.
    Sagawa T; Takahashi M; Sato T; Sato Y; Lu Y; Sumiyoshi T; Yamada Y; Iyama S; Fukaura J; Sasaki K; Hamada H; Miyanishi K; Takayama T; Kato J; Niitsu Y
    Mol Ther; 2004 Dec; 10(6):1043-50. PubMed ID: 15564136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
    Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
    Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously.
    Qian Q; Sham J; Che X; Xu J; Xue H; Cui Z; Zhu B; Wu M
    Chin Med J (Engl); 2002 Aug; 115(8):1213-7. PubMed ID: 12215295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.